Olema Pharmaceuticals Q2 EPS $(0.49) Beats $(0.73) Estimate
Portfolio Pulse from Benzinga Newsdesk
Olema Pharmaceuticals reported Q2 losses of $(0.49) per share, beating the analyst consensus estimate of $(0.73) by 32.88 percent. This represents a 40.24 percent increase over losses from the same period last year.
August 08, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Olema Pharmaceuticals' Q2 losses were less than expected, which could positively impact the stock in the short term.
Olema Pharmaceuticals reported lower than expected losses for Q2, beating analyst estimates by 32.88%. This is generally seen as positive news by investors and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100